BRAF^V600E mutation is associated with better prognoses in radioactive iodine refractory thyroid cancer patients treated with multi-kinase inhibitors: a retrospective analysis of registered clinical trials.

ABSTRACT:

Background

The antiangiogenic multi-kinase inhibitors (MKIs) apatinib, donafenib, and anlotinib have demonstrated satisfactory efficacy in radioactive iodine refractory differentiated thyroid cancer (RAIR-DTC) in their phase II/III trials. However, the potential impact factors on the efficacy of these MKIs remain unclear.

Methods

RAIR-DTC patients enrolled in clinical trials of apatinib, donafenib, and anlotinib in our center were retrospectively reviewed. The Kaplan-Meier method was used to examine the relationship between clinicopathological variables and progression-free survival (PFS) and overall survival (OS), followed by a multivariate Cox analysis on PFS.

Results

A total of 71 progressive RAIR-DTC patients were reviewed, of which 26.7% were treated by anlotinib

SUBMITTER: Sun D 

PROVIDER: S-EPMC11808998 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature